Clinical trial · Interventional
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
An Exploratory Study to Evaluate Safety and Efficacy of the Neoantigen Personalized mRNA Vaccine AK154 Monotherapy or in Combination With AK104 or AK112,and the Sequential mFOLFIRINOX Regimen as Adjuvant Therapy in Surgically Resectable Pancreatic Ductal Adenocarcinoma
NCT06913218CI-TRIAL-00088186not yet recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
| Pancreas Cancer, Duct Cell Adenocarcinoma | Pancreatic Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AK154 | Biological | — | UNRESOLVED |
| Cadonilimab | Biological | — | UNRESOLVED |
| Ivonescimab (SMT112 or AK112) Injection | Biological | — | UNRESOLVED |
| mFOLFORINOX | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pancreatic Cancer
- description
- Resectable PDAC
- interventionNames
- Biological: AK154
- Biological: Cadonilimab
- Biological: Ivonescimab (SMT112 or AK112) Injection
- Drug: mFOLFORINOX
Primary outcomes (2)
- measure
- DLT
- timeFrame
- Day 1 to Day 21 after the first tumour vaccine was administrated
- description
- Percentage of subjects who meet the criteria of DLT in DLT observation period
- measure
- AE
- timeFrame
- From ICF up to 30days after last study treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Voluntarily signed the informed consent form and complied with protocols requirements * Patients with radiographically resectable primary pancreatic tumors * Histopathology or cytology confirmed resected PDAC with macroscopic complete resection (R0 and R1) * Pancreatic cancer surgical staging per AJCC 8th edition staging: T 1-3, N0-2, M0 * ECOG 0 or 1 * Life expectancy ≥ 6 months * Surgical complications have recovered, * Adequate organ function * Patients with fertility are willing to use an adequate method of contraception. Exclusion Criteria: * The presence of other pathologic types * Participating in another clinical study * Have received treatment for pancreatic cancer, including chemotherapy, radiation therapy, targeted therapy, immunotherapy,etc * Plan to receive a live-attenuated vaccine within 28 days prior to initiation of study treatment or during the study treatment or within 90 days after the end of study treatment * Severe infection occurs within 4 weeks prior to the first dose * Requiring systemic therapy with glucocorticoids or other immunosuppressive drugs within 14 days prior to initial administration. * Acute pancreatitis or subclinical pancreatitis * Active autoimmune disease * Allergic to immunotherapies and related drugs * History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. * Splenectomy history * Active tuberculosis * Known or highly suspected history of interstitial pneumonia. * Clinically significant liver disease * Uncontrolled or severe cardiovascular disease. * Severe bleeding tendency or history of coagulopathy * Active malignancy within the last 3 years * Active syphilis infection * Any other situations that are not suitable for inclusion in this study judged by investigator.
References
Publications (0)
Data not yet available
No reference posted for this study.